Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

ملخص مفصل

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026, in Washington, D.C.

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks

VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers

SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026, in Washington, D.C.

Viking presented results from an exploratory analysis of data from its Phase 2 VENTURE clinical trial of VK2735, dosed as a weekly subcutaneous injection, in a poster session on Sunday. The analysis examines changes in obesity severity and cardiometabolic parameters after 13 weeks of treatment. Data from the analysis showed that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one body mass index (BMI) category, compared with 15% of those receiving placebo. None of the VK2735-treated participants experienced an increase in BMI category.

Shifts in BMI category from baseline to Week 13 Among VK2735 Treated vs. Placebo

Notes: 1) Class definitions as follows. Class III = BMI ≥ 40; Class II = BMI ≥ 35 – 39.9; Class I = BMI ≥ 30 – 34.9; Overweight = BMI ≥ 25 – 29.9; Normal weight = BMI ≥ 20 – 24.9. 2) 12% of placebo participants transitioned from Class I to Class II.

Notes: Values expressed as Mean (standard deviation). Analyses based on observed values at baseline and Week 13.

These findings were presented at ObesityWeek by Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM, Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center, in a poster presentation entitled "Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study."

"This…

مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.